FDA’s Enhanced Role and SBOM Mandate Further Validates Market for Cybeats’ SBOM Studio

Posted on by

TORONTO, March 31, 2023 /PRNewswire/ – Cybeats Technologies Corp. (“Cybeats” or the “Company”) (CSE: CYBT) is pleased to provide an update following the FDA’s new Refuse-to-Accept (RTA) Authority as of March 29, 2023. The FDA’s new Authority, moving from its previous recommended guidance…